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In the past few decades, remarkable advances have been made in the field of 
immunology and molecular biology. Even though the efficacy level, protein binding capacity 
and other pharmacological parameters are extraordinary, formulations have become more 
challenging in terms of making drugs or antigens reach specific sites of action, the release 
rate of a drug at the site of action, proper presentation of an antigen by antigen-presenting 
cells or dendritic cells and other pharmacokinetic and pharmacodynamic parameters of 
finished drug products and vaccines. The purpose of this review is to present a brief 
overview of the challenges to drug targeting, especially vaccines, as well as of different 
approaches designed to overcome these barriers. 
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The concept of a targeted drug delivery 
system (TDDS), which was first proposed by 
Paul Ehrlich in 1902, in which he called the 
hypothetical drug a magic bullet, is still 
under extensive research (Ehrlich, 1902; 
Strebhardt and Ullrich, 2008; Patel et al. 2010). 
This targeted drug delivery system (TDDS) 
releases its drug at a preselected biosite in a 
controlled manner. Recent knowledge to 
explore drug delivery systems has reached a 
certain level where scientists are clear about 
the pathophysiology of most diseases, as well 
as the physiological and anatomical 
interventions of the body’s systems (Xiao et 
al. 2002; Reichel, 2006; Bae and Park, 2011; 
Madhuri et al. 2011). Furthermore, drug-
targeting challenges have become more 
sophisticated in terms of more efficacy, less 
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toxicity of the drug design, higher 
immunogenicity of vaccines and higher 
expression levels of gene therapy 
(Morenweiser, 2005; Patil et al. 2005; Madhuri 
et al. 2011; Sarkar and Suresh, 2011; Malabadi 
et al. 2011). The introduction of the carrier 
system concept in recent years has opened up 
a new era for drug targeting (Bae and Park, 
2011). For example, activation of dendritic 
cells (DCs) through a nanocarrier-based 
system has made it possible to efficiently 
create and develop immunogenic DNA 
vaccines (Xiang et al. 2010). DCs play a critical 
role in the generation of the antigen-specific 
antiviral and antitumor T cell immune 
responses (Inaba et al. 1995; Jiang et al. 1995; 
Banchereau and Steinman, 1998; Den Haan et 
al. 2000; Nestle et al. 2001; Cerundolo et al. 
2004; van Broekhoven et al. 2004; Mahnke et 
al. 2005; Tacken et al. 2006; Wang et al. 2005, 
2009). DCs present in peripheral tissues are 
immature but sufficiently able to respond to 
dangerous signals by expressing various 
surface receptors (maturation), indicating the 
presence of an infection (Inaba et al. 1995; 
Jiang et al. 1995; Banchereau and Steinman, 
1998; Den Haan et al. 2000; Nestle et al. 2001; 
Guermonprez et al. 2002; Cerundolo et al. 
2004; Wang et al. 2005, 2009). Scientists are 
currently investigating different types of 
nanocarrier systems such as multiple 
emulsions, liposomes, and polymeric 
nanoparticles as delivery systems to achieve 
different levels of formulation goals 
(Shahiwala et al. 2007). 
 
TARGETING CHALLENGES FOR 
VACCINES AND THERAPEUTICS 
Successful drug targeting involves a 
clear understanding of various distributional 
and rate processes, as well as drug 
metabolism and disposition (Rapaka, 1995; 
Mizuno et al. 2003). Drug distribution and 
rate processes depend on the nature of 
biological and cellular membranes, the 
distribution of drug receptors, local blood 
flow, enzyme system, etc. (Rapaka, 1995; 
Mizuno et al. 2003). Scientists have already 
achieved a benchmark in physiology and 
molecular biology which demonstrates a 
number of aspects that are at a standstill 
remain challenging for drug targeting 
(Rapaka, 1995; Mizuno et al. 2003). Among 
them, brain targeting for vaccines and 
therapeutics is one of the major challenging 
areas for scientists due to its outstanding 
anatomical and physiological features 
(Mizuno et al. 2003; de Boer and Gaillard, 
2007). These are: (1) Bone skull, an anatomical 
barrier for transdermal delivery systems; (2) 
Blood-brain barrier (BBB), a physiological 
barrier for less lipophilic and large molecular 
sized proteins as only small and lipid-soluble 
drugs can penetrate across the BBB; (3) Blood 
cerebrospinal fluid barrier (BCSFB), a 
biochemical barrier for vaccines and 
therapeutics (Mizuno et al. 2003; de Boer and 
Gaillard, 2007; Pavan et al. 2008). 
 
For drugs (or vaccines) whose targets 
are located in the cytoplasm or nucleus of a 
cell, the challenge to physiological barriers is 
the need to diffuse through the viscous 
cytosol to access particular cytoplasmic 
targets where the site of action is located 
(Mozafari, 2006). A barrier such as the 
nuclear membrane is a formidable challenge 
for the passage of oligonucleotides, plasmid 
DNA, etc. (Mozafari, 2006). The viscous 
cytosolic biochemical barrier is another 
challenge for drug candidates like peptides 
since chemical drug molecules have peculiar 
biochemical composition of different types of 
enzymes (Mozafari, 2006). 
 
The rapid clearance of foreign particles 
from circulation by macrophages lining the 
sinusoids in the liver, spleen and bone 
marrow is one of the most important 
mechanisms in host defense against infections 
(Staub, 1994). The distinct physiological 
functions of the components of the bone 
marrow make it challenging for drug 
targeting, gene therapy or vaccine targeting 
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(Staub, 1994). This distinct feature is due to 
sinuses, a relatively large blood vessel 
forming a barrier called the marrow blood 
barrier (MBB) (Staub, 1994). Its selective 
uptake of molecules from the circulation 
system into the reticuloendothelial system 
(RES) of bone marrow offers a tremendous 
challenge for delivery system formulations 
(Vyas and Khar, 2002). The majority of 
pathogens invade the body cavity through 
one of the mucosal routes that cover the aero-
digestive or urinogenital tract, eye 
conjunctiva, inner ear and the ducts of all 
endocrine glands (Staub, 1994; Vyas and 
Khar, 2002). These areas where almost 80% of 
all immunocytes are present are treated as the 
first line defense system of a body. In 
traditional vaccination, where whole cells or 
attenuated whole cells are generally used as 
vaccine formulation with adjuvants, mucosal 
routes are prime targets (Ongkudon et al. 
2011). For these mucosal vaccines a number 
of challenges have to be faced by formulation 
scientists. Furthermore, adequate binding of 
antigen to the target cells for proper 
presentation depends on proper attachment 
and colonization, which is challenging for 
non-invasive bacteria as well as penetration 
and replication, which are further challenging 
for invasive bacteria and viruses (Ongkudon 
et al. 2011). A new concept that has been 
introduced recently to rid the limitation of 
mucosal vaccine is the DNA vaccine, in 
which recombinant protein or DNA is used, 
and which are safer than mucosal vaccines, 
which are less immunogenic (Ongkudon et al. 
2011). Thus, challenges that still exist are to 
develop a proper delivery system or adjuvant 
to make vaccines more immunogenic. 
 
TARGETING STRATEGIES 
To overcome the different levels of 
challenges of a body’s systems, different drug 
delivery approaches have been adapted. 
These fall into three categories: (a) Physical 
approaches; (b) biological approaches; (c) 
chemical approaches (Rapaka, 1995; Mizuno 
et al. 2003). Physical delivery approaches, 
such as biodegradable polymers based on 
nanoparticles, liposomes, osmotic pumps, 
implants, etc., are to modifying drug 
pharmacokinetics without essentially 
affecting the specificity where biological 
targeting approaches are based on the 
biological carrier system (bio-conjugation) to 
cross biological barriers and to ensure site-
specific drug release (Misra et al. 2003; Bae 
and Park, 2011). Chemical drug delivery 
systems (CDSs), another emerging concept in 
drug delivery systems and initially defined 
by Bodor and Brewster as chemical 
compounds produced by synthetic chemical 
reactions to form covalent bonds between the 
drug and specifically designed “carrier” and 
other moieties, include, for example, pro-
drugs (Zuo et al. 2008; Reichel, 2006; Bae and 
Park, 2011). The targeting strategy can either 
be active or passive (Bodor and Brewster, 
1991). Sometimes, due to the nature of the 
challenge and target site, some alternative 
approaches, like inverse targeting, is an 
alternative way of passive targeting; 
alternatively, a number of approaches have 
been engaged for a single target such as dual 
or double targeting and combination 
targeting strategies (Bodor and Brewster, 
1991; Zuo et al. 2008; Strebhardt and Ullrich, 
2008; Patel et al. 2010; Bae and Park, 2011). 
 
Active targeting strategy 
In active targeting, the delivery system 
is designed by attaching the drug delivery 
system – something like an antibody, a carrier 
protein, or a ligand – allowing it to establish a 
complex with the target cell where specific 
receptors are present (Allen, 2002; Mohanraj 
and Chen, 2006; Bae and Park, 2011; Yoo et al. 
2011). So, it is obvious that active targeting 
approaches depend on (1) the specificity of 
the delivery system and the homing devices 
where drugs will be attached, for example, 
antibody, carrier protein albumin, sugar, 
vitamins, etc. and (2) the capacity of drug 
delivery from the complex at a specific 
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receptor site (Allen, 2002; Mohanraj and 
Chen, 2006; Bae and Park, 2011; Yoo et al. 
2011). This targeting approach can be further 
classified into three different levels based on 
target site: (1) First order targeting (organ 
compartmentalization) where target sites are 
the capillary bed of organs or tissues like the 
lymphatic cavity, peritoneal cavity, cerebral 
ventricles, lungs, eyes, etc.; (2) Second order 
targeting (cellular targeting) where target 
sites are specific cells rather than normal cells 
like Kupffer cells in the liver, tumor cells, etc.; 
(3) Third order targeting (intracellular 
targeting) where target sites are intracellular 
spaces like the cytoplasm or organelles such 
as the nucleus, etc. (Charman et al. 1999; 
Santini Jr. et al. 2000; Kopecek, 2003). 
Stimulating the body’s immune response 
against cancer cells by gene therapy (e.g., a 
DNA cancer vaccine) is a recent area for an 
active third order targeted drug delivery 
system (Palmer et al. 2002; Bae and Park, 
2011). Cancer cell death may be induced by 
introducing cancer cells with genes encoding 
apoptosis. This most critical approach for 
intracellular targeting involves four steps: (1) 
interaction of the active delivery system with 
the extracellular plasma membrane receptor; 
(2) the drug will enter the cell by receptor-
mediated endocytosis; (3) fusion of drug with 
lysosomes; (4) degradation of the homing 
device and release of the drug or RNA into 
the intracellular target (Palmer et al. 2002; Bae 
and Park, 2011). 
 
Passive targeting strategy 
Simply, passive targeting is an approach 
where vaccines or therapeutics can escape the 
body defense mechanism like metabolism, 
excretion or opsonisation, followed by 
phagocytosis (Couvreur and Vauthier, 2006; 
Bae and Park, 2011). So they can easily be 
circulated throughout the body system and 
subsequently reach target receptors. These 
approaches are mainly governed by different 
characteristics of the delivery system 
depending on the body’s general defensive 
system (Couvreur and Vauthier, 2006; Bae 
and Park, 2011). For example, if the delivery 
system releases a drug having a molecular 
weight (MW) > 30 kDa, it can avoid quick 
renal excretion as the MW is ≤ 30 kDa, 
making it prone to quick renal excretion (Bae 
and Park, 2011). To do this, formulators 
normally design drug or vaccine molecules 
with different types of carrier systems which 
increase their critical MW (Jain, 2008). 
However, when increasing the MW, scientists 
have to consider the size; for example, a > 200 
nm size delivery system can blockade the 
blood capillary (Jain, 2008). In vaccine design, 
the size is a crucial factor for DC maturation 
otherwise the vaccine will show lower 
immunogenic responses (Jain, 2008). The 
monophasic phagocytic system (MPS) needs 
a hydrophobic system (treated as a 
xenobiotic) and opsonisation followed by 
phagocytosis and subsequent removal from 
the circulation system into the reticulo- 
endothelial system for excluding from the 
body. In this case, scientists should address 
the hydrophilicity of the delivery system, 
which that can be achieved in different ways 
(Jain, 2008). For example, incorporation of a 
hydrophilicity-imparting agent such as 
polyethylene glycol (PEG) (Jain, 2008). 
Surface charge of the delivery system is 
another important factor which also 
determines the period to which it can stay 
and circulate throughout the body’s systems 
(Jain, 2008). As only neutrally charged 
systems can circulate, they will otherwise be 
expelled either by Kupffer cells in the liver 
(for example, a negatively charged system) or 
by opsonisation (as a positively charged 
system is recognized by opsonin as a foreign 
particle) (Moghimi and Patel, 1998). Again, in 
the case of a vaccine formulation, these types 
of reorganization could be used in antigen-
presenting cells (APCs) to boost immune 
responses (Moghimi and Patel, 1998; Jain, 
2008). 
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For a non-viral gene delivery system, 
synthetic vectors for gene delivery must be 
able to overcome a range of barriers (Jackson 
et al. 2006; Martin and Rice, 2007). These are: 
(1) stability in the bloodstream; (2) 
reorganization by receptors of the target cell 
and subsequent entrance into the cell 
cytoplasm; (3) if it contains mRNA, 
cytoplasm will be the end of the journey; if it 
contains DNA, it will reach the nucleus across 
the nuclear membrane for transcription 
(Jackson et al. 2006; Martin and Rice, 2007). In 
passive targeting, all these body defensive 
challenges can be overcome using a 
nanocarrier system (Jackson et al. 2006; 
Martin and Rice, 2007). As DNA is a 
polyanion and can bind with polycations 
such as poly(L-lysine) or poly(ethylene imine), 
it can make polyplexes which are 
approximately 100 nm in size and discreet in 
nature. This size allows it to penetrate 
through small pores of the membrane 
(Jackson et al. 2006; Martin and Rice, 2007; 
Jain, 2008). This can be protected by surface 
coating with a steric stabilizer like PEG 
followed by a multivalent hydrophilic lateral 
stabilizer such as poly[N-(2-hydroxypropyl) 
methacrylamine] (pHPMA) which makes it a 
stealth vector for escaping the body’s defense 
system (Jackson et al. 2006; Martin and Rice, 
2007). This will be necessary for receptor-
mediated uptake of these stabilized 
polyplexes by receptor-positive cells, using 
transferrin, vascular endothelial growth 
factor (VEGF) and basic fibroblast growth 
factor (bFGF) as targeting ligands. Following 
receptor-mediated uptake into cells, DNA 
polyplexes are usually found in the 
endosomes (Kircheis et al. 2001). Their entry 
from the endosome into the cytoplasm can be 
mediated in various ways like the peptide 
melittin or pH-responsive peptides, etc. 
(Kircheis et al. 2001). In the cytoplasm, 
polymer coating becomes destabilized by 
reducing the disulphide bonds and releasing 
DNA for cytoplasmic expression (Kircheis et 
al. 2001). However, entry of exogenous DNA 
into the nucleus is extremely difficult, 
particularly in non-dividing cells, where the 
nuclear membrane provides a persistent 
barrier to entry (Kircheis et al. 2001; Jackson et 
al. 2006; Martin and Rice, 2007). For nucleus 
entry, DNA should be designed especially 
with a nuclear localization sequence (NLS) 
which ensures efficient nuclear uptake and 
subsequent nuclear expression (Lam and 
Dean, 2010). An alternative approach to 
enhanced nuclear uptake is based on the 
mechanisms employed by an adenovirus, 
where the adenovirus hexon protein mediates 
efficient transcytoplasmic transfer of the 
virion, delivering it to the nuclear pore 
complex for expression (Lam and Dean, 
2010). 
 
In the passive targeting interventions, for 
example pathophysiological approaches, if 
we wish to target tumor cells in the liver for a 
chemical therapeutic or a DNA vaccine (e.g., 
an anti TGF-β DNA vaccine), we can 
formulate it to be coated with a proper carrier 
system having a proper size and charge but 
hydrophobic in nature (Kresina, 2001; Lam 
and Dean, 2010). After administration, it will 
be euphonized and sent to the liver cells but 
cannot be destroyed due to its coating system 
until it reaches the tumor cells in the liver as 
the inner temperature of tumor cells will be 
higher than normal liver cells (Kresina, 2001). 
Again, as an example of a physicochemical 
approach, if a drug is highly soluble and 
excreted out quickly, MW enhancement (>30 
kDa) is a rapid approach to avoid renal 
excretion and give more time to reach the 
target site (Kresina, 2001). 
 
Other targeting strategies 
Inverse targeting strategy 
It is sometimes possible to escape the body’s 
defense system by an alternative way of 
passive targeting approaches, also known as 
the inverse targeting approach (Paasonen, 
2010). For example, the rapid uptake of a 
colloidal carrier system by the 
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reticuloendothelial system (RES) can be 
escaped by pre-treatment of blank colloidal 
carriers or macromolecules like dextran 
sulphate to saturate the RES rather than 
passive targeting approaches that involve an 
increment in molecular size (Paasonen, 2010). 
This approach leads to a RES blockade and 
consequent impairment of the host defense 
system (Paasonen, 2010). 
 
Dual targeting strategy 
The dual targeting approach is an efficient 
approach against virus infection and its drug 
resistance where the carrier system used to 
load the antiviral drug has an synergistic 
effect on the action of the drug (Kircheis et al. 
2001; Martin and Rice, 2007; Jain, 2008; Bae 
and Park, 2011). Based on this approach, 
bioconjugates can be prepared using different 
types of natural and synthetic molecules such 
as antibodies, immunetoxins, CD4, 
glycoprotein, etc. (Kircheis et al. 2001; Martin 
and Rice, 2007; Jain, 2008; Bae and Park, 
2011). Conjugation can be achieved using 
various non-covalent and covalent 
techniques. These dual targeting approaches 
can also be implemented for an enzyme 
immune assay system (e.g., antibody-enzyme 
conjugates), vaccine research and antibody 
production (e.g., Hepten-carrier conjugates), 
etc. These become important research issues 
especially for non-viral gene delivery systems 
and cancer vaccines (Kircheis et al. 2001; 
Martin and Rice, 2007; Jain, 2008; Bae and 
Park, 2011). 
 
Double targeting strategy 
This new concept of drug delivery is 
designed to improve the drug therapeutic 
index in terms of selectivity and control 
release (Kircheis et al. 2001; Martin and Rice, 
2007; Jain, 2008; Bae and Park, 2011). 
Selectivity to a target site is ensured by 
linking with antibodies that are specific either 
to a particular antigen or cell lines expressing 
a cell-specific receptor. Controlling the release 
of a drug depends on the device or system 
which will carry the drug and can be 
stimulated or activated spatially after 
reaching the target site which is solely 
governed by the linked antibody’s specificity 
(Kircheis et al. 2001; Martin and Rice, 2007; 
Jain, 2008; Bae and Park, 2011). Therefore, the 
system will contain a drug loader that can be 
controlled spatially and a linked antibody to 
govern its selection to specific molecular sites 
(Kircheis et al. 2001; Martin and Rice, 2007; 
Jain, 2008; Bae and Park, 2011). 
 
Combination targeting strategy 
The combination targeting approach is an 
upgraded strategy for the delivery of site-
specific proteins and peptides. It is equipped 
with carriers, polymers and homing devices 
of molecular specificity that could provide a 
direct approach to the target site (Roth et al. 
2008). This approach is being adapted to 
avoid a number of shortcomings of proteins 
and peptide delivery techniques (Roth et al. 
2008). These are: (1) permeability problem of 
large peptides; (2) chemical decomposition of 
homing devices; (3) non-specific drug release 
due to target tissue heterogenecity; (4) 
immune response against the system, etc. 
(Roth et al. 2008). The problem of 
permeability can be solved by modification of 
peptides using natural polymers such as PEG. 
A pro-drug is another strategy for avoiding 
the chemical decomposition of homing 
devices (Roth et al. 2008). For site-specific 
drug release, scientists can employ either 
different types of carrier systems or spatially 
controlled devices (Roth et al. 2008). 
 
CARRIER-BASED PHYSICAL DELIVERY 
APPROACHES 
Nanoparticles 
In the field of controlled and targeted drug 
delivery system, biodegradable and 
biocompatible polymers based on colloidal 
carriers are recently playing a governing role 
in research and development (Kircheis et al. 
2001; Martin and Rice, 2007; Jain, 2008; Bae 
and Park, 2011). The concept of a 
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nanoparticle, among them, is the most 
prominent branch of study that can be used 
for site-specific delivery as well as for 
controlling the release from burst to pulsatile 
approaches (Petros and DeSimone, 2010; Bae 
and Park, 2011; Wani et al. 2011). 
Nanoparticles, are sub-nanosized colloidal 
structures, generally composed of natural, 
synthetic or semi-synthetic biodegradable 
and biocompatible polymers such as gelatin, 
albumin, poly(lactic acid), poly(lactic glycolic 
acid), etc. (Petros and DeSimone, 2010; Bae 
and Park, 2011; Wani et al. 2011). Among the 
available natural hydrophilic polymers such 
as gelatin, albumin, etc., most of them suffer a 
number of disadvantages: (1) lack of 
uniformity; (2) chance of biodegradation 
before reaching the target site due to less 
physical stability; (3) antigenic response, etc. 
(Bae and Park, 2011). Drugs can either be 
entrapped into the reservoir or the matrix 
system or be absorbed onto the surface of 
these particulate systems (Petros and 
DeSimone, 2010; Bae and Park, 2011; Wani et 
al. 2011). 
 
Like all colloidal drug carrier systems, the 
bio-distribution and bio-fate of nanoparticles 
can be described as rapid opsonization and 
followed by excretion by the RES 
macrophages (Bae and Park, 2011). About 
90% intravenously injected nanoparticles are 
absorbed by the liver and spleen within 
minutes (Petros and DeSimone, 2010). This 
unique feature of nanoparticles has been 
engaged for nanoparticles based on passive 
targeting chemotherapy of RES-localized 
tumors in the liver where a drug will reach 
rapidly and the release of that drug, from 
burst to controlled pattern, will depend on 
the polymeric characteristics of those carrier 
nanoparticles (Petros and DeSimone, 2010). 
For tissue targeting other than RES requires 
the escape from rapid absorption into the 
liver RES. This can be achieved by increasing 
particle size (< 100 nm) and hydrophilicity of 
the nanoparticles (Petros and DeSimone, 
2010; Wani et al. 2011). The process of 
escaping RES absorption has already been 
discussed in passive targeting approaches. 
Nanoparticles coated with polysorbate open 
the way of greater transportation of a drug 
into the brain across the BBB (Petros and 
DeSimone, 2010). Polysorbate-loaded 
nanoparticles link with apolipoprotein E of 
blood plasma which in turn interact with 
LDL (low density lipoprotein) receptors on 
endothelial cells in the brain capillary and 
lead to their cellular uptake through the BBB. 
Sub-cutaneous nanoparticle injection is a 
useful tool for chemotherapy against 
lymphatic tumors or metastasis (Petros and 
DeSimone, 2010; Wani et al. 2011). 
 
Surface modification of nanoparticles 
offer numerous opportunities for drug 
targeting as it allows the specific bio-chemical 
interaction between the surface of 
nanoparticles and the proteins or receptors 
expressed on target cells (Petros and 
DeSimone, 2010; Wani et al. 2011). Beside this, 
surface modification or engineering can be 
employed to prepare stealth nanoparticles 
through steric stabilization to deter the 
opsonization process, or prepare site-specific 
antibody-coated nanoparticles, magnetically 
guided nanoparticles and bioadhesive 
nanoparticles (Petros and DeSimone, 2010; 
Wani et al. 2011). 
 
The liposome has tremendous potential as 
the drug delivery system for both passive and 
active targeting approaches due to its 
enormous structural diversity as well as 
composition possibilities (Cao and Suresh, 
1998). Simply, liposomes are organized 
phospholipid vesicles that have been used to 
encapsulate protein and DNA (Ratnam et al. 
2006). Lipid composition makes them unique 
for rapid interaction with microphages and 
DCs via cell surface receptors, such as CD1a, 
after complement activation (Cao and Suresh, 
1998; Ratnam et al. 2006). It allows them to 
escape the challenges imposed by the body’s 
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defense system. Passive approaches that 
target macrophages can be used to deliver 
immunomodulators, as well as cytotoxic and 
anti-microbial agents (Ratnam et al. 2006). 
Liposomes can also couple to an anti-
transferrin receptor antibody at the BBB and 
easily cross through endocytosis (Ratnam et 
al. 2006). Multi-drug resistance (MDR), which 
is another tremendous challenge for 
formulation scientists, can be overcome by a 
liposomal delivery system (Mecke et al. 2006). 
Most of MRD is related with the over 
expression of some drug efflux pumps, 
known as P-glycoprotein pumps (PGPs) and 
Multi-drug resistance associated protein 
pumps (MRPs) as these pumps efflux and 
reject positively charged amphipathic drugs 
(mostly anticancer drugs) from cells (Mecke et 
al. 2006; Ratnam et al. 2006). This action may 
cause less intracellular drug accumulation 
which leads to drug resistance. A negatively 
charged liposomal system can easily avoid 
the efflux process of the MRP (Mecke et al. 
2006; Ratnam et al. 2006). Engineered 
liposomes and lipid complexes such as pH-
sensitive liposomes, immunoliposomes, 
cationic liposomes (lipoplexes), fusogenic 
liposomes, genosomes, etc., which show 
much potential in gene delivery, have a clear 
advantage of high transfection efficiency over 
other non-viral vector systems (Mecke et al. 
2006; Ratnam et al. 2006). pH-sensitive 
liposomes undergo slight destabilization in 
the mild acidic medium of endosomes after 
endocytosis and cause the selective release of 
mRNA into the cytoplasm followed by 
subsequent translation. Immunoliposomes 
can absorb DNA on their surface and transfer 
it into the cytoplasm without allowing 
lysosomal destruction (Cao and Suresh, 1998; 
Mecke et al. 2006; Ratnam et al. 2006). 
Genosomes, a complex formulation of DNA 
with various cationic liposomes (lipoplex), is 
a colloidal suspension that can transfer DNA 
from the site of injection to the target cell 
surface though biological fluid such as serum 
and release it into the nucleus of target cells 
for DNA expression (Mecke et al. 2006; 
Ratnam et al. 2006). Liposomes can be 
classified based on composition, its 
applications or diameters (Cao and Suresh, 
1998; Mecke et al. 2006; Ratnam et al. 2006). 
Traditional bilayer and multilayer 
liposomes are physically unstable and rapidly 
leak the encapsulated material (Mecke et al. 
2006; Ratnam et al. 2006). This problem can be 
solved by using the concept of polymerized 
liposome nanoparticles which can maintain 
their size and integrity even upon oral 
administration. Nanoparticle-based vaccines 
can carry multivalent surface antigens like 
liposomes, sugar, protein, etc. which elicit a 
significant increase in the immune response 
(Mecke et al. 2006; Ratnam et al. 2006). 
 
BIOCONJUGATES AS BIOLOGICAL 
DELIVERY APPROACH 
Bioconjugation, a biological drug 
targeting approach, involves the covalent or 
non-covalent linkage of two or more 
molecules to form a novel complex having 
combined properties of each of them to 
deliver the drug to the specific target site by 
avoiding enzymatic degradation pathways, 
rapid RES uptake and other challenges 
(Mohanraj and Chen, 2006). Examples of bio-
conjugates include several vaccines, 
pegylated proteins and antibody-linked 
molecules. The goal of bioconjugates depends 
mainly on the nature of biocarriers (Mohanraj 
and Chen, 2006). Highly investigated 
biocarriers can be categorized into: (I) 
Macromolecules – for example, antibody, 
immunotoxins, oligonucleotides, CD4, 
interleukins, interferons, transferrins, insulin, 
etc.; (II) Enzymes; (III) Glycoproteins 
(Mohanraj and Chen, 2006). The most 
common types of bioconjugates in localized 
drug targeting approaches vary from simple 
types of bioconjugates like small molecule 
(such as biotin) to protein bioconjugates, 
protein-protein bioconjugates (such as the 
coupling of an antibody to an enzyme), to 
very complex types such as oligosaccharides, 
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nucleic acids, synthetic polymers (such as 
PEG, poly-L-lysine) and carbon nanotube 
bioconjugates, etc. (Mohanraj and Chen, 
2006). 
 
PRO-DRUG, AS CHEMICAL DELIVERY 
APPROACH 
The term “pro-drug” was first introduced 
in 1958 to describe compounds that undergo 
biotransformation prior to their therapeutic 
activity (Rautio et al. 2008). It is a chemically 
modified inactive drug moiety which will be 
converted into an active one by enzymatic 
action after reaching specific target sites 
(Rautio et al. 2008). By applying pro-drug 
technology, an example of a chemical 
targeting approach, the clinical usefulness of 
a drug molecule may be enhanced without 
modifying the pharmacological activity of the 
parent drug. In addition, there should be 
considerable knowledge on a particular 
enzyme system and its molecular and 
functional characteristics upon which the 
release of the drug after appropriate cleavage 
from the drug carrier depend (Rautio et al. 
2008). 
 
Oral drug absorption, which is rate 
limiting for poorly soluble and poorly 
permeable drugs, can be enhanced by using 
gastrointestinal enzymes that target a pro-
drug based chemical delivery system (Rautio 
et al. 2008). For colon-specific drug delivery, 
the glycosidase activity of colonic microflora 
can be used by chemically modifying the 
drug molecule into its glycoside derivatives 
(Rautio et al. 2008). This pro-drug is 
hydrophilic in nature and is not absorbed by 
the intestine but when it reaches the colon, it 
can be effectively cleaved by bacterial 
glycosidases of the microflora to release and 
be absorbed by colonic mucosa (Rautio et al. 
2008). The delivery of peptides to the brain is 
challenging due to their hydrophilic nature 
and their rapid degradation by peptidases 
localized within the capillary endothelium. 
There is promise in transferring ester-linked 
peptide pro-drugs through the BBB without 
peptidase activity (Rautio et al. 2008). Glycin 
pro-drugs such as Milacemide (2-n-
pentylaminoacetamide) are another example 
of a pro-drug-based brain targeting approach 
where Monoamine oxidase (MAO), a 
mitochondrial enzyme which catalyzes the 
oxidative deamination of amines, plays a vital 
role in the cleavage of the glycin linkage from 
the active drug after crossing the BBB (Balant 
et al. 1990; Rautio et al. 2008). Glycin, which is 
incorporated chemically as a glycinamide 
linkage with bioactive peptides, enhances its 
lipophilicity to ensure its transportation 
across the BBB (Balant et al. 1990; Rautio et al. 
2008). Beside this lipid-mediated 
transportation, drug molecules can be 
targeted to the central nervous system (CNS) 
based on their interaction with endogenous 
transport systems located within the brain 
capillary endothelium or the neuroepithelial 
cells of the choroid plexus (Balant et al. 1990; 
Rautio et al. 2008). These endogenous 
transport systems are: (a) carrier-mediated 
transport (CMT), (b) active efflux transport 
(AET) and (c) receptor-mediated transport 
(RMT). Among them, CMT systems that 
show structure-specific (stereospecific) 
transportation mainly transport nutrients, 
vitamins or hormones into the CNS (Balant et 
al. 1990; Rautio et al. 2008). Pro-drug chemical 
approaches through either (i) the 
modification of drug into a “pseudonutrient” 
structure or (ii) the conjugation of a drug with 
a nutrient shows promise in CMT systems for 
neuroactive molecules. L-DOPA is the first 
example of a CMT-targeted, pro-drug-based 
delivery system (Balant et al. 1990; Rautio et 
al. 2008). 
 
CONCLUSION 
Different types of drug delivery strategies 
that are engaged to overcome the barrier 
systems for drug targeting have been 
systematically described in brief. The 
selection of suitable strategies, which is a 
critical step, depends on the characteristics of 
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physiological barriers and available tools and 
techniques. Drug targeting is clearly not only 
a challenging field in pharmaceutical sciences 
and medicine but also a fascinating field for 
innovation as it is now not limited to 
traditional concepts rather than the 
combination concepts of biology, chemistry, 
physics and engineering. 
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